Invivyd Q3 revenue $13.1M (+41% YoY); net loss narrows; IND cleared for VYD2311

Invivyd, Inc.

2025-Q3 EPS reported -$0.30 vs consensus -$0.08 ▼ miss (-267.6%)

PEMGARDA net product revenue $13.1M in Q3 2025, up 41% YoY and 11% QoQ.
Net loss $10.5M ($0.06 diluted EPS) vs $60.7M ($0.51) in Q3 2024; R&D spend fell to $8.0M from $57.9M.
Cash $85.0M at Sep 30; >$100M after Oct ATM; $57.5M gross proceeds from Aug 2025 offering.
FDA cleared IND for VYD2311; pivotal REVOLUTION program (DECLARATION N=1770, LIBERTY N=210) starts near year-end 2025, data mid-2026.
Board adds Dr. Paul Bolno; Kristie Kuhl named CCO; pipeline expansion into RSV and measles.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.